Blog

The 15th World Congress on Targeting Mitochondria is set to take place in Berlin from October 28-30, 2024, promising a platform for front-line discussions and major insights into mitochondrial research. Credit: World Mitochondria Society (WMS) The 15th World Congress on Targeting Mitochondria is set to

Laval, February 14, 2024 – A research team of Canadian and French scientists, led by INRS professor Maya Saleh, has been investigating immunotherapy resistance in certain patients with hepatocellular carcinoma (HCC) associated with steatotic liver disease. The findings are published in the journal Cell Reports. Credit:

FOR IMMEDIATE RELEASE Credit: From left, Evanthia Roussos Torres, Elizabeth Jaffee, Roisin Connolly and Vered Stearns. FOR IMMEDIATE RELEASE A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel

Lung cancer ranks second among the most common cancers worldwide and is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC), accounting for 85% of all lung cancers, has a very low overall survival (OS) and a high postoperative recurrence rate despite improved

New York, NY [February 14, 2024]—Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University

Scientists at Cold Spring Harbor Laboratory (CSHL) and the University of California, Davis have reached a new breakthrough in pancreatic cancer research—eight years in the making. It could help slow the disease’s deadly spread. Credit: Tuveson lab/Cold Spring Harbor Laboratory Scientists at Cold Spring Harbor

Chemotherapy can save lives, but often a cancer patient may be resistant to their prescribed chemotherapy, which costs the patient valuable time. Chemoresistance is a topic that researchers need to understand better so that they can match the right type of chemo to the right

Reston, VA—Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in the February issue of The Journal of Nuclear Medicine. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80

New York, NY – February 13, 2024 – The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation (SWCRF) have selected six investigators to receive three grants for their collaborative, two-year program aimed at improving our understanding of the links between aging and

A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer types that have lacked such tools until now, according to a new study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.